NZ595630A - Methods for preventing and/or treating degenerative disorders of the central nervous system - Google Patents
Methods for preventing and/or treating degenerative disorders of the central nervous systemInfo
- Publication number
- NZ595630A NZ595630A NZ595630A NZ59563010A NZ595630A NZ 595630 A NZ595630 A NZ 595630A NZ 595630 A NZ595630 A NZ 595630A NZ 59563010 A NZ59563010 A NZ 59563010A NZ 595630 A NZ595630 A NZ 595630A
- Authority
- NZ
- New Zealand
- Prior art keywords
- nervous system
- central nervous
- preventing
- methods
- degenerative disorders
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 230000003412 degenerative effect Effects 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810109P | 2009-04-09 | 2009-04-09 | |
| PCT/US2010/030470 WO2010118282A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating degenerative disorders of the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595630A true NZ595630A (en) | 2013-04-26 |
Family
ID=42934882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595630A NZ595630A (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating degenerative disorders of the central nervous system |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8304429B2 (https=) |
| EP (1) | EP2416655B1 (https=) |
| JP (1) | JP5634498B2 (https=) |
| CN (1) | CN102448306B (https=) |
| AU (1) | AU2010233187B2 (https=) |
| BR (1) | BRPI1015472A2 (https=) |
| CA (1) | CA2758187C (https=) |
| ES (1) | ES2505243T3 (https=) |
| IL (1) | IL215584A (https=) |
| NZ (1) | NZ595630A (https=) |
| WO (1) | WO2010118282A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940766B2 (en) * | 2009-04-09 | 2015-01-27 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
| WO2011049737A1 (en) * | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| SI2490532T1 (sl) | 2009-10-19 | 2017-03-31 | Amicus Therapeutics, Inc. | Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema |
| CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2013070981A2 (en) * | 2011-11-08 | 2013-05-16 | University Of Central Florida Research Foundation, Inc. | Treating er stress related disorders by stabilizing intracellular calcium homeostasis |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| WO2015095963A1 (en) | 2013-12-23 | 2015-07-02 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| CN110177572A (zh) * | 2016-09-12 | 2019-08-27 | 史蒂文·霍夫曼 | 用于治疗痴呆的组合物 |
| AR110074A1 (es) * | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
| BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
| EA202091693A1 (ru) | 2018-01-12 | 2021-04-14 | Бристол-Маерс Сквибб Компани | Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения |
| CN119606967B (zh) * | 2024-12-13 | 2025-09-05 | 合肥工业大学 | 氯雷他定在制备用于预防和治疗血管钙化药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024391A1 (en) * | 1994-03-09 | 1995-09-14 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| US20060079533A1 (en) * | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US6670625B1 (en) * | 2002-06-18 | 2003-12-30 | Ge Medical Systems Global Technology Company, Llc | Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner |
| JP2006507359A (ja) * | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| CN101541172A (zh) * | 2005-06-08 | 2009-09-23 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| US20080009156A1 (en) | 2006-07-10 | 2008-01-10 | Malin Glen K | System and method for bonding coaxial cable |
| US8940766B2 (en) * | 2009-04-09 | 2015-01-27 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
-
2010
- 2010-04-09 CA CA2758187A patent/CA2758187C/en not_active Expired - Fee Related
- 2010-04-09 NZ NZ595630A patent/NZ595630A/xx not_active IP Right Cessation
- 2010-04-09 AU AU2010233187A patent/AU2010233187B2/en not_active Ceased
- 2010-04-09 JP JP2012504880A patent/JP5634498B2/ja active Active
- 2010-04-09 CN CN201080024142.1A patent/CN102448306B/zh not_active Expired - Fee Related
- 2010-04-09 WO PCT/US2010/030470 patent/WO2010118282A1/en not_active Ceased
- 2010-04-09 US US12/757,144 patent/US8304429B2/en not_active Expired - Fee Related
- 2010-04-09 BR BRPI1015472A patent/BRPI1015472A2/pt not_active Application Discontinuation
- 2010-04-09 EP EP10762468.6A patent/EP2416655B1/en active Active
- 2010-04-09 ES ES10762468.6T patent/ES2505243T3/es active Active
-
2011
- 2011-10-06 IL IL215584A patent/IL215584A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IL215584A (en) | 2016-11-30 |
| ES2505243T3 (es) | 2014-10-09 |
| US20100261753A1 (en) | 2010-10-14 |
| CN102448306B (zh) | 2014-07-02 |
| AU2010233187B2 (en) | 2015-10-08 |
| JP5634498B2 (ja) | 2014-12-03 |
| EP2416655B1 (en) | 2014-06-25 |
| CA2758187C (en) | 2017-03-07 |
| US8304429B2 (en) | 2012-11-06 |
| EP2416655A1 (en) | 2012-02-15 |
| CN102448306A (zh) | 2012-05-09 |
| BRPI1015472A2 (pt) | 2015-11-24 |
| HK1168005A1 (zh) | 2012-12-21 |
| CA2758187A1 (en) | 2010-10-14 |
| WO2010118282A1 (en) | 2010-10-14 |
| AU2010233187A1 (en) | 2011-11-03 |
| EP2416655A4 (en) | 2012-09-05 |
| IL215584A0 (en) | 2011-12-29 |
| JP2012523430A (ja) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595630A (en) | Methods for preventing and/or treating degenerative disorders of the central nervous system | |
| NZ595629A (en) | Methods for preventing and/or treating lysosomal storage disorders | |
| NZ598145A (en) | Folate-targeted diagnostics and treatment | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| HK1211525A1 (en) | Laquinimod and pridopidine for treating neurodegenerative disorders | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MY162067A (en) | Combination therapy for treatment of patients with neurological disorders and cerebral infarction | |
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| EP4374873A3 (en) | Methods for treating or preventing opthalmological conditions | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| WO2008133928A3 (en) | Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders | |
| EP2521592A4 (en) | INTENSITY-MODULATED ROTATION THERAPY WITH CONTINUOUS BED ROTATION / SHIFTING AND SIMULTANEOUS 3D IMAGING | |
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UA98136C2 (ru) | Применение аклидиния для лечения респираторных заболеваний | |
| WO2011009020A3 (en) | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | |
| MX2012007813A (es) | Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. | |
| MX2009004561A (es) | Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor. | |
| BR112016020381A8 (pt) | sistemas e métodos para liberação de drogas para tratamento do câncer de bexiga com gencitabina. | |
| EP3970712A3 (en) | Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof | |
| MY196979A (en) | Method of treating disease by auricular anesthesia of cranial nerves | |
| WO2011050008A9 (en) | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE AGENT HAS BEEN CORRECTED TO 1441794, IPONZ, 2. , 205 VICTORIA STREET, TE ARO, WELLINGTON 6011, NZ; 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ Effective date: 20130404 Free format text: THE AGENT HAS BEEN CORRECTED TO 1028818, WRAYS, WRAYS #1701, 24B MOOREFIELD ROAD, JOHNSONVILLE, WELLINGTON 6037, NZ Effective date: 20130404 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 APR 2017 BY CPA GLOBAL Effective date: 20140306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2018 BY CPA GLOBAL Effective date: 20170303 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2019 BY CPA GLOBAL Effective date: 20180301 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 APR 2020 BY CPA GLOBAL Effective date: 20190307 |
|
| LAPS | Patent lapsed |